General Information of Drug Combination (ID: DCD2CSH)

Drug Combination Name
Vericiguat Nitroglycerin
Indication
Disease Entry Status REF
Coronary Artery Disease Phase 1 [1]
Component Drugs Vericiguat   DM7MDBE Nitroglycerin   DMQ2491
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Vericiguat
Disease Entry ICD 11 Status REF
Heart failure BD10-BD13 Approved [2]
Vericiguat Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Soluble guanylyl cyclase (GUCY2D) TTWNFC2 GUC2D_HUMAN Modulator [2]
------------------------------------------------------------------------------------
Indication(s) of Nitroglycerin
Disease Entry ICD 11 Status REF
Angina pectoris BA40 Approved [3]
Diabetic foot ulcer BD54 Approved [4]
Nitroglycerin Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Soluble guanylate cyclase (GCS) TT23PYC GCYA1_HUMAN; GCYB1_HUMAN Modulator [5]
Epidermal growth factor receptor (EGFR) TTGKNB4 EGFR_HUMAN Activator [4]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT02617550) Vericiguat Drug-drug Interaction With Nitroglycerin in Stable Coronary Artery Disease Patients
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7053).
4 Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24.
5 Activators of soluble guanylate cyclase for the treatment of male erectile dysfunction. Int J Impot Res. 2002 Feb;14(1):8-14.